Polyphor Ltd.
11
0
0
8
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 80/100
27.3%
3 terminated/withdrawn out of 11 trials
72.7%
-13.8% vs industry average
18%
2 trials in Phase 3/4
0%
0 of 8 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (11)
Pivotal Study in VAP Suspected or Confirmed to be Due to Pseudomonas Aeruginosa
Role: lead
Pivotal Study in Nosocomial Pneumonia Suspected or Confirmed to be Due to Pseudomonas
Role: lead
Dose Escalation of POL6326 in Combination With Eribulin in Patients With Metastatic Breast Cancer
Role: lead
Pharmacokinetics, Safety and Efficacy of POL7080 in Patients With Ventilator Associated Pseudomonas Aeruginosa Pneumonia
Role: lead
DDI Study to Investigate Interaction Between Amikacin and POL7080
Role: lead
Safety, Efficacy and PK/PD of POL7080 in Patients With Exacerbation of Non-cystic Fibrosis Bronchiectasis.
Role: lead
Pharmacokinetics and Safety of POL7080 in Patients With Renal Impairment
Role: lead
CXCR4 Antagonism for Cell Mobilisation and Healing in Acute Myocardial Infarction (CATCH-AMI)
Role: lead
Safety and Efficacy of POL6326 for Mobilization/Transplant of Sibling Donor in Patients With Hematologic Malignancies
Role: lead
Safety and Efficacy of POL6326 for Mobilization of Hematopoietic Stem Cells in Healthy Volunteers
Role: lead
Exploratory Study on POL6326 in Stem Cell Mobilization
Role: lead
All 11 trials loaded